Alimera Sciences, Inc. announced that it has completed enrollment for the company?s Synchronicity Study, a prospective, open-label clinical study evaluating the safety and efficacy of YUTIQ (fluocinolone acetonide intravitreal implant 0.18mg) in the treatment of chronic non-infectious uveitis and related intraocular inflammation. The Synchronicity Study is a multicenter, open label study evaluating YUTIQ in chronic inflammation. The Synchronicity Study currently has enrolled 110 patient eyes in approximately 25 sites around the U.S. Patients who meet the entry criteria receive YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg as an intravitreal injection in the designated study eye.

The treatment period is 36 months, with data capture for this study being the first 24 months of YUTIQ drug treatment.